MeMed Raises Over $70 Million to Advance Pioneering Point-Of-Care Platform and Immune-Based Test for Distinguishing Bacterial Versus Viral Infections Round includes leading international investors, further solidifying MeMed's leadership in host-based diagnostics HAIFA, Israel, September 20, 2018-- MeMed today announced the completion of a new round of financing totaling over $70 million, with participation from new and existing investors including Ping An Global Voyager Fund, Foxconn, Caesarea Medical Holdings, Clal Insurance, Phoenix Insurance, OurCrowd, Social Capital, WTI, Horizons Ventures, and high-net-worth executives renowned for early investments in industry-changing companies.